Facility
Boehringer Ingelheim - Taizhou, Jiangsu China
Operated by Boehringer Ingelheim Animal Health →CN
58M EUR investment; 125M dose/yr capacity; partnership with China Medical City; first local Ingelvac PRRS MLV production; Asias leading vaccine facility
0
Inputs produced
0
Goods downstream
0
Incidents on record
0
Stories